Arvinas Inc (ARVN)

Apr 01, 2025

Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 29.9% in March - MarketBeat

Apr 01, 2025

Apr 01, 2025

BIT Capital GmbH Has $5.05 Million Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Apr 01, 2025

Mar 31, 2025

Arvinas (NASDAQ:ARVN) Hits New 52-Week LowHere's What Happened - MarketBeat

Mar 31, 2025

Mar 29, 2025

Where are the Opportunities in (ARVN) - news.stocktradersdaily.com

Mar 29, 2025

Mar 27, 2025

Arvinas stock hits 52-week low at $7.91 amid market challenges - Investing.com India

Mar 27, 2025

Mar 27, 2025

Arvinas stock hits 52-week low at $7.91 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

Groundbreaking First Human Data: New PROTAC Drug Takes Aim at Parkinson's Disease - Stock Titan

Mar 27, 2025

Mar 26, 2025

Arvinas (NASDAQ:ARVN) Shares Down 5.1%Time to Sell? - MarketBeat

Mar 26, 2025

Mar 25, 2025

Arvinas FY2025 EPS Forecast Increased by Cantor Fitzgerald - MarketBeat

Mar 25, 2025

Mar 24, 2025

Noah Berkowitz Sells 8,658 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock - MarketBeat

Mar 24, 2025

Mar 23, 2025

Arvinas (NASDAQ:ARVN) Trading Up 4%Here's Why - MarketBeat

Mar 23, 2025

Mar 21, 2025

Wedbush Brokers Raise Earnings Estimates for Arvinas - MarketBeat

Mar 21, 2025

Mar 20, 2025

Wedbush Has Positive Outlook for Arvinas Q1 Earnings - MarketBeat

Mar 20, 2025

Mar 19, 2025

Arvinas chief medical officer sells $74,372 in common stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance

Mar 19, 2025

Mar 19, 2025

Arvinas chief medical officer sells $74,372 in common stock - Investing.com India

Mar 19, 2025

Mar 19, 2025

Arvinas Chief Medical Officer Sells Shares to Cover Tax Obligations - TradingView

Mar 19, 2025

Mar 19, 2025

(ARVN) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 19, 2025

Mar 18, 2025

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds? - Yahoo Finance

Mar 18, 2025

Mar 17, 2025

Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook By Investing.com - Investing.com Australia

Mar 17, 2025

Mar 17, 2025

Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook - Investing.com

Mar 17, 2025

Mar 17, 2025

Arvinas (NASDAQ:ARVN) Price Target Cut to $12.00 by Analysts at Morgan Stanley - MarketBeat

Mar 17, 2025

Mar 17, 2025

Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance

Mar 17, 2025

Mar 17, 2025

The Goldman Sachs Group Downgrades Arvinas (NASDAQ:ARVN) to Neutral - MarketBeat

Mar 17, 2025

Mar 17, 2025

Arvinas (NASDAQ:ARVN) Given New $32.00 Price Target at Guggenheim - MarketBeat

Mar 17, 2025

Mar 16, 2025

Arvinas (NASDAQ:ARVN) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat

Mar 16, 2025

Mar 16, 2025

Bank of America Issues Pessimistic Forecast for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat

Mar 16, 2025

Mar 16, 2025

Arvinas (NASDAQ:ARVN) Hits New 1-Year LowHere's What Happened - MarketBeat

Mar 16, 2025

Mar 15, 2025

Oppenheimer Downgrades Arvinas (NASDAQ:ARVN) to Market Perform - MarketBeat

Mar 15, 2025

Mar 15, 2025

Arvinas (NASDAQ:ARVN) Downgraded to Neutral Rating by Wedbush - MarketBeat

Mar 15, 2025

Mar 14, 2025

Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN

Mar 14, 2025

Mar 14, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

Mar 14, 2025

Mar 14, 2025

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J - Yahoo Finance

Mar 14, 2025

Mar 14, 2025

Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects - Seeking Alpha

Mar 14, 2025